Effects of Astragalus membranaceus on systemic lupus erythematosus in a mouse model of pregnancy

BACKGROUND: This study used astragalus membranaceus (AM) to treat systemic lupus erythematosus (SLE) model mice during pregnancy, aiming to explore the role of AM in Helper T cell 17 (Th17) differentiation and SLE during pregnancy. METHODS: We used lipopolysaccharide to constructed the SLE mouse model. AM decoction given by intragastric administration lasted from the eighth week of the mouse age until the mouse was killed. We estimated the messenger RNA levels of IL‐17a and Rorc, counted the Th17 cell number and examined the levels of cytokines including interleukin (IL)‐12, tumor necrosis factor α, interferon gamma, IL‐17A in mouse serum. Periodic acid‐Schiff staining and renal glomerular/tubulointerstitial (TI) score were used to evaluate the progression of lupus nephritis (LN). RESULTS: AM treatment improved the conception rate and increased the number and average weight of fetuses in SLE mice. It significantly decreased the urinary albumin/creatinine ratios and reduced the glomerular scores and TI scores in the pregnant SLE mice. AM gavage significantly decreased the weight of spleen, mesenteric lymph node, total splenocytes and T cells, and the expression of proinflammatory factors. Furthermore, AM treatment reduced the ratio of Th17 cells and the expression levels of RORγt and IL‐17A. CONCLUSION: AM significantly improved pregnancy outcomes and inhibited lupus nephritis during pregnancy in SLE mice.